TCM
CRNX icon

Tekla Capital Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Tekla Capital Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$1.42M Hold
78,529
– – 0.06% 123
2023
Q1 		$1.26M Buy
78,529
+32,668
+71% +$605K 0.05% 134
2022
Q4 		$839K Buy
+45,861
New +$808K 0.03% 136

Other funds holding CRNX

DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Tekla Capital Management's CRNX Position: Q2 2023 in Review

Tekla Capital Management held its Crinetics Pharmaceuticals (CRNX) position steady in Q2 2023 at 78,529 shares worth $1.42M. The position accounts for 0.06% of the portfolio, ranked #123.

Tekla Capital Management first reported a position in CRNX in Q4 2022 and has held it in 3 quarters since. 140 funds tracked by Wall St. Rank hold CRNX as of Q2 2023.

  • Tekla Capital Management held 78,529 shares of Crinetics Pharmaceuticals worth $1.42M as of Q2 2023.
  • Tekla Capital Management left its Crinetics Pharmaceuticals share count unchanged in Q2 2023.
  • Crinetics Pharmaceuticals made up 0.06% of Tekla Capital Management's portfolio in Q2 2023, its #123 holding.
  • Tekla Capital Management first reported a position in Crinetics Pharmaceuticals in Q4 2022 and has held it in 3 quarters since.
  • 140 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.